Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
| Autor: | Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Gastroenterology Breast Neoplasms Male Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Prospective Studies Registries Neoplasm Metastasis Young adult Prospective cohort study Survival rate Aged Aged 80 and over Chemotherapy business.industry Hazard ratio Estrogen Receptor alpha Middle Aged medicine.disease Metastatic breast cancer Confidence interval Survival Rate Treatment Outcome 030104 developmental biology Oncology 030220 oncology & carcinogenesis Female Receptors Progesterone business Follow-Up Studies Cohort study |
| Zdroj: | Clinical Cancer Research. 26:1105-1113 |
| ISSN: | 1557-3265 1078-0432 0161-5068 |
| Popis: | Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs). Experimental Design: SystHERs (NCT01615068) was an observational, prospective registry study of U.S.-based patients with newly diagnosed HER2-positive MBC. Endpoints included treatment patterns and clinical outcomes. Results: Of 977 eligible patients (enrolled from 2012 to 2016), 70.1% (n = 685) had HR-positive and 29.9% (n = 292) had HR-negative disease. Overall, 59.1% (405/685) of patients with HR-positive disease received any first-line endocrine therapy (with or without HER2-targeted therapy or chemotherapy); 34.9% (239/685) received HER2-targeted therapy + chemotherapy + sequential endocrine therapy. Patients with HR-positive versus HR-negative disease had longer median overall survival (OS; 53.0 vs 43.4 months; hazard ratio, 0.70; 95% confidence interval, 0.56–0.87). Compared with patients with high HR-positive staining (10%–100%, n = 550), those with low HR-positive staining (1%–9%, n = 60) received endocrine therapy less commonly (64.2% vs 33.3%) and had shorter median OS (53.8 vs 40.1 months). Similar median OS (43.4 vs 40.1 months) was observed in patients with HR-negative versus low HR-positive tumors (1%–9%). Conclusions: Despite evidence that first-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy improves survival in patients with HR-positive, HER2-positive disease, only 34.9% of patients in this real-world setting received such treatment. Patients with low tumor HR positivity (1%–9%) had lower endocrine therapy use and worse survival than those with high tumor HR positivity (10%–100%). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|